Mercury Laboratories Ltd
₹
None%
- close price
About
Incorporated in 1962, Mercury Laboratories
Ltd manufactures and exports Pharmaceutical items of gynec and pediatrics
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
16 Apr - Resignation of Head of Injectable Production (SMP) for career advancement.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Reg, 2015- Imposition Of Penalty
16 Apr - Penalty of INR 32,197 imposed for ITC disallowance; company to appeal.
-
Change In Email Address Of RTA MUFG Intime India Pvt Ltd
11 Apr - Change of email address for RTA communication.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Apr - Certificate under Reg 74(5) SEBI (DP) Regulation for the quarter ended on March 31, 2025 is attached
-
Closure of Trading Window
26 Mar - Closure of trading window effective April 01, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2007
from bse
-
Financial Year 2006
from bse
Product Categories:[1]
Analgesic, Anti-inflammatory, Anti-pyretic, Anthelmintic, Antibiotic, Anti-coagulant,
Anti- platelet, Bleeding agents, Anti-fungal, Anti-hypertensive drugs, Anti malarial drugs, Cardiovascular System, Central Nervous System, Eye, Gastro-intestinal system, Hypoglycemic (Anti-diabetic), Multivitamin, Protein supplement, Respiratory System, Anti- allergic, Steroids, Urinary system, Uterine stimulant, Tablets, Oral Liquids, Small Volume Parenterals, Eye/Ear Drops